Xilio Therapeutics, Inc. Finance Lease, Principal Payments
Xilio Therapeutics, Inc. (XLO) reported Finance Lease, Principal Payments of $49.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-03-23
- Xilio Therapeutics, Inc. finance lease, principal payments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Xilio Therapeutics, Inc. finance lease, principal payments for the quarter ending 2024-09-30 was $7.00K, a 68.18% decline year-over-year.
- Xilio Therapeutics, Inc. finance lease, principal payments for the quarter ending 2024-06-30 was $21.00K, a 0.00% change year-over-year.
- Xilio Therapeutics, Inc. finance lease, principal payments for the quarter ending 2024-03-31 was $21.00K, a 0.00% change year-over-year.
- Xilio Therapeutics, Inc. finance lease, principal payments for fiscal 2024 was $49.00K, a 42.35% decline from fiscal 2023.
- Xilio Therapeutics, Inc. finance lease, principal payments for fiscal 2023 was $85.00K, a 0.00% change from fiscal 2022.
- Xilio Therapeutics, Inc. finance lease, principal payments for fiscal 2022 was $85.00K, a 0.00% change from fiscal 2021.
- Xilio Therapeutics, Inc. finance lease, principal payments for fiscal 2021 was $85.00K, a 14.14% decline from fiscal 2020.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $7.00K derived: sum of 2 quarters · filed 2026-03-23 | $28.00K derived: sum of 3 quarters · filed 2026-03-23 | $49.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $28.00K derived: sum of 2 quarters · filed 2025-11-13 | $49.00K 10-Q · filed 2025-11-13 | $70.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $42.00K 10-Q · filed 2025-08-14 | $63.00K derived: sum of 3 quarters · filed 2025-08-14 | $85.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $21.00K 10-Q · filed 2025-05-08 | $42.00K derived: sum of 2 quarters · filed 2025-05-08 | $64.00K derived: sum of 3 quarters · filed 2025-05-08 | $85.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $43.00K derived: sum of 2 quarters · filed 2025-03-11 | $64.00K derived: sum of 3 quarters · filed 2025-03-11 | $85.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $43.00K derived: sum of 2 quarters · filed 2024-11-07 | $64.00K 10-Q · filed 2024-11-07 | $85.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $42.00K 10-Q · filed 2024-08-08 | $63.00K derived: sum of 3 quarters · filed 2024-08-08 | $85.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $21.00K 10-Q · filed 2024-05-14 | $42.00K derived: sum of 2 quarters · filed 2024-05-14 | $64.00K derived: sum of 3 quarters · filed 2024-05-14 | $85.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $43.00K derived: sum of 2 quarters · filed 2024-04-01 | $64.00K derived: sum of 3 quarters · filed 2024-04-01 | $85.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $43.00K derived: sum of 2 quarters · filed 2023-11-09 | $64.00K 10-Q · filed 2023-11-09 | $86.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $42.00K 10-Q · filed 2023-08-14 | $64.00K derived: sum of 3 quarters · filed 2023-08-14 | $85.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-09 | $43.00K derived: sum of 2 quarters · filed 2023-05-09 | $64.00K derived: sum of 3 quarters · filed 2023-05-09 | $85.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $43.00K derived: sum of 2 quarters · filed 2023-03-02 | $64.00K derived: sum of 3 quarters · filed 2023-03-02 | $85.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $42.00K derived: sum of 2 quarters · filed 2022-11-09 | $63.00K 10-Q · filed 2022-11-09 | $91.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $42.00K 10-Q · filed 2022-08-09 | $70.00K derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $21.00K 10-Q · filed 2022-05-12 | $49.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $99.00K 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $71.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |